

1 **Title: Host-Microbe Multiomic Profiling Reveals Age-Dependent COVID-19**  
2 **Immunopathology**

3  
4 **One sentence summary:** We observed age-dependent immune dysregulation at the  
5 transcriptional, protein and cellular levels, manifesting in an imbalance of inflammatory responses  
6 over the course of hospitalization, and suggesting potential new therapeutic targets.

7  
8 **Authors:**

9 Hoang Van Phan<sup>1†</sup>, Alexandra Tsitsiklis<sup>1†</sup>, Cole P. Maguire<sup>2</sup>, Elias K. Haddad<sup>3</sup>, Patrice M. Becker<sup>4</sup>,  
10 Seunghee Kim-Schulze<sup>5</sup>, Brian Lee<sup>5</sup>, Jing Chen<sup>6,7</sup>, Annmarie Hoch<sup>6</sup>, Harry Pickering<sup>8</sup>, Patrick Van  
11 Zalm<sup>6</sup>, Matthew C. Altman<sup>9</sup>, Alison D. Augustine<sup>4</sup>, Carolyn S. Calfee<sup>1</sup>, Steve Bosinger<sup>10</sup>, Charles  
12 Cairns<sup>3</sup>, Walter Eckalbar<sup>1</sup>, Leying Guan<sup>11</sup>, Naresh Doni Jayavelu<sup>9</sup>, Steven H. Kleinstein<sup>12</sup>, Florian  
13 Krammer<sup>5</sup>, Holden T. Maecker<sup>13</sup>, Al Ozonoff<sup>6</sup>, Bjoern Peters<sup>14</sup>, Nadine Rouphael<sup>10</sup>, IMPACC  
14 Network, Ruth R. Montgomery<sup>12</sup>, Elaine Reed<sup>8</sup>, Joanna Schaenman<sup>8</sup>, Hanno Steen<sup>6</sup>, Ofer Levy<sup>6</sup>,  
15 Joann Diray-Arce<sup>6</sup>, \*Charles R. Langelier<sup>1,15</sup>

16  
17 **Affiliations:**

18 <sup>1</sup>University of California San Francisco

19 <sup>2</sup>University of Texas Austin

20 <sup>3</sup>Drexel University/Tower Health Hospital

21 <sup>4</sup>National Institute of Allergy and Infectious Diseases/National Institutes of Health

22 <sup>5</sup>Icahn School of Medicine at Mount Sinai

23 <sup>6</sup>Precision Vaccines Program, Boston Children's Hospital

24 <sup>7</sup>Research Computing, Department of Information Technology, Boston Children's Hospital

25 <sup>8</sup>David Geffen School of Medicine, University of California Los Angeles

26 <sup>9</sup>Benaroya Research Institute

27 <sup>10</sup>Emory University

28 <sup>11</sup>Yale School of Public Health

29 <sup>12</sup>Yale School of Medicine

30 <sup>13</sup>Stanford University

31 <sup>14</sup>La Jolla Institute for Immunology

32 <sup>15</sup>Chan Zuckerberg Biohub San Francisco

33

34 †These authors contributed equally

35 \*Correspondence: [chaz.langelier@ucsf.edu](mailto:chaz.langelier@ucsf.edu)

36 **Abstract:**

37 Age is a major risk factor for severe coronavirus disease-2019 (COVID-19), yet the mechanisms  
38 responsible for this relationship have remained incompletely understood. To address this, we  
39 evaluated the impact of aging on host and viral dynamics in a prospective, multicenter cohort of  
40 1,031 patients hospitalized for COVID-19, ranging from 18 to 96 years of age. We performed  
41 blood transcriptomics and nasal metatranscriptomics, and measured peripheral blood immune  
42 cell populations, inflammatory protein expression, anti-SARS-CoV-2 antibodies, and anti-  
43 interferon (IFN) autoantibodies. We found that older age correlated with an increased SARS-CoV-  
44 2 viral load at the time of admission, and with delayed viral clearance over 28 days. This  
45 contributed to an age-dependent increase in type I IFN gene expression in both the respiratory  
46 tract and blood. We also observed age-dependent transcriptional increases in peripheral blood  
47 IFN- $\gamma$ , neutrophil degranulation, and Toll like receptor (TLR) signaling pathways, and decreases  
48 in T cell receptor (TCR) and B cell receptor signaling pathways. Over time, older adults exhibited  
49 a remarkably sustained induction of proinflammatory genes (e.g., *CXCL6*) and serum chemokines  
50 (e.g., *CXCL9*) compared to younger individuals, highlighting a striking age-dependent impairment  
51 in inflammation resolution. Augmented inflammatory signaling also involved the upper airway,  
52 where aging was associated with upregulation of TLR, IL17, type I IFN and IL1 pathways, and  
53 downregulation TCR and PD-1 signaling pathways. Metatranscriptomics revealed that the oldest  
54 adults exhibited disproportionate reactivation of herpes simplex virus and cytomegalovirus in the  
55 upper airway following hospitalization. Mass cytometry demonstrated that aging correlated with  
56 reduced naïve T and B cell populations, and increased monocytes and exhausted natural killer  
57 cells. Transcriptional and protein biomarkers of disease severity markedly differed with age, with  
58 the oldest adults exhibiting greater expression of TLR and inflammasome signaling genes, as well  
59 as proinflammatory proteins (e.g., IL6, *CXCL8*), in severe COVID-19 compared to mild/moderate  
60 disease. Anti-IFN autoantibody prevalence correlated with both age and disease severity. Taken  
61 together, this work profiles both host and microbe in the blood and airway to provide fresh insights  
62 into aging-related immune changes in a large cohort of vaccine-naïve COVID-19 patients. We  
63 observed age-dependent immune dysregulation at the transcriptional, protein and cellular levels,  
64 manifesting in an imbalance of inflammatory responses over the course of hospitalization, and  
65 suggesting potential new therapeutic targets.

66

67 **Main text:**

68 **Introduction:**

69 Age is a major risk factor for severe Coronavirus disease 2019 (COVID-19), with older  
70 adults experiencing markedly greater rates of acute respiratory distress syndrome (ARDS) and  
71 death compared to younger individuals<sup>1-3</sup>. Even with vaccination rates above 90%, adults over 75  
72 years of age are 140 times more likely to die if infected with SARS-CoV-2<sup>4</sup>. Despite these striking  
73 epidemiological associations, the biological mechanisms underlying the impact of aging on  
74 COVID-19 remain incompletely understood.

75 Observational cohort studies of healthy adults<sup>5,6</sup> demonstrate that aging leads to baseline  
76 increases in plasma concentrations of proinflammatory cytokines<sup>5,7</sup>, several of which (e.g., IL6)  
77 are well-known biomarkers of COVID-19 severity, suggesting potential connections between the  
78 pathophysiology of human aging and COVID-19<sup>7</sup>. Juxtaposed against this state of aging-  
79 associated inflammation are functional impairments in innate and adaptive immune signaling,  
80 observed during vaccination of aged individuals<sup>8-11</sup>. Furthermore, recent human *in vitro* data  
81 indicates that aging results in impaired production of type I interferons in monocytes and dendritic  
82 cells following Toll-like receptor (TLR) ligation, suggesting disrupted innate immunity<sup>12-16</sup>.

83 Comparative upper respiratory tract transcriptional profiling has demonstrated that mild  
84 SARS-CoV-2 infection induces a more robust innate and adaptive immune response in children  
85 compared to adults<sup>17,18</sup>. Paradoxically, amongst adults hospitalized for COVID-19, a more robust  
86 immune response underlies the pathogenesis of severe disease, suggesting more complicated  
87 relationships between aging and host defense for older individuals. Adding further complexity,  
88 and highlighting the need for additional investigation, is the association between increased age,  
89 development of anti-interferon autoantibodies (autoAbs), and disease severity<sup>2,19,20</sup>.

90 The pathophysiology of COVID-19 involves a dynamic relationship between SARS-CoV-  
91 2 and the host immune response<sup>21,22</sup>, yet studies of COVID-19 and aging<sup>1</sup> have assessed each  
92 independently. Furthermore, heterogeneity in human physiology necessitates a large sample size

93 to optimally study aging and host immunity. To address these gaps, we leverage data from 1,031  
94 adults hospitalized for COVID-19 enrolled in the IMPACC (IMMunoPhenotyping Assessment in a  
95 COVID-19 Cohort) cohort<sup>2,23</sup>, and perform a multiomic, host/microbe systems immunoprofiling  
96 study of aging.

97 From 2,523 longitudinally collected blood and nasal swab samples, we investigate the  
98 impact of aging on SARS-CoV-2 viral load, SARS-CoV-2 antibody (Ab) levels, host gene  
99 expression, inflammatory protein expression, immune cell populations, and the nasal microbiome.  
100 Our study leverages a robust multicenter cohort to gain new insights into aging and immunity by  
101 integrating host and microbe data. This work builds on landmark clinical studies demonstrating  
102 that age is a major risk factor for COVID-19 severity<sup>1-3</sup>, assesses the generalizability of early  
103 translational studies that included smaller numbers of study participants<sup>7,12,24,25</sup>, and generates  
104 fresh insights into age-dependent COVID-19 pathophysiology that could assist in developing age-  
105 specific therapeutic interventions and biomarkers of disease severity.

106


## 107 **Results:**

### 108 **Study cohort**

109 We analyzed blood and nasal swab specimens from 1,031 adults with COVID-19 enrolled  
110 in the IMPACC cohort from 20 hospitals across the United States<sup>2,23</sup> (Fig. 1, Supp. Table 1).  
111 Participants were grouped into quintiles based on age for analyses (18-46, 47-54, 55-62, 63-70,  
112 and 71-96 years old), ranging from 187 to 223 participants (median 206 participants) per age  
113 group (Fig. 2a). We analyzed age distributions across five previously defined COVID-19 disease  
114 trajectory groups<sup>2</sup>, ranging from mild disease with brief length of hospital stay (TG1) to severe  
115 disease and death (TG5). We found that advanced age was significantly associated with disease  
116 trajectory group (Fig. 2b) and mortality (Fig. 2c). To investigate host immunologic and microbial  
117 features associated with age, we employed a wide range of assays at baseline (within 72 hours  
118 of hospital admission) and longitudinally post-hospital admission (Fig. 1, Methods). These

119 included transcriptional profiling of PBMCs and nasal swabs, soluble serum immune protein  
 120 profiling, whole blood mass cytometry (CyTOF), nasal metatranscriptomics, SARS-CoV-2 IgG  
 121 assays, and anti-IFN- $\alpha$  autoAb measurements.

122



123

124 **Fig. 1: Graphical study overview.** This study evaluated 1,031 COVID-19 patients between the ages of 18 and 96  
 125 enrolled in the IMPACC cohort at 20 hospitals across the United States. Blood (PBMCs, plasma and serum) and nasal  
 126 swab samples were collected at up to 6 visits over 28 days and processed for RNA sequencing, proteomics, mass  
 127 cytometry, and serology.

128

129 **Aging is associated with higher SARS-CoV-2 viral load, impaired viral clearance, and lower**  
 130 **SARS-CoV-2 antibody levels**

131

132

133

134


135

136

Older adults had a significantly higher SARS-CoV-2 viral load at Visit 1, measured in reads per million (rpM) from nasal swab RNA sequencing ( $P = 0.0011$ , Fig. 2d), a measurement that highly correlated with qPCR cycle threshold ( $P < 2.2e-16$ , Supp. Fig. 1). This age-related increase in viral load was not explained by differences in time from symptom onset (Supp. Fig. 2). Longitudinal analysis also revealed significant differences in viral load dynamics, with the oldest adults demonstrating reduced viral clearance compared to the youngest adults ( $P = 0.0024$ , Fig.

137 2e). We also assessed anti-SARS-CoV-2 receptor binding domain (RBD) IgG levels across the  
138 five age groups, and found that the oldest adults had lower levels at Visit 1 (Supp. Fig. 3a) and  
139 lower Ab production over time (Supp. Fig. 3b).

140




141

142 **Fig. 2: Older adults have more severe COVID-19 and higher SARS-CoV-2 viral loads.** (a) Age distribution of the  
143 participant cohort. (b, c) Box plot showing the relationship between patients' age and (b) trajectory group severity or (c)  
144 mortality. (d) Nasal swab SARS-CoV-2 viral load at Visit 1 (reads per million (rpM) measured by metatranscriptomics)  
145 in each age group. In (b-d), P-values were calculated using Kruskal-Wallis test. (e) Nasal swab SARS-CoV-2 viral load  
146 over time in each age group. P-value was calculated with generalized additive mixed effects modeling.

147

## 148 **Age-dependent differences in immune cell populations**

149 We quantified differences in proportions of immune cell populations in the peripheral blood  
150 by mass cytometry (CyTOF) to assess whether aging altered cell frequencies<sup>23</sup>. Using a panel of  
151 43 Abs designed to identify cell lineages in whole blood samples from Visit 1, we found 21 cell  
152 types (Fig. 3a) significantly associated with participant age (adjusted  $P < 0.05$ , Fig. 3b). Increased  
153 age correlated with higher proportions of circulating classical monocytes (CD14<sup>+</sup> CD16<sup>-</sup>), non-  
154 classical monocytes (CD14<sup>-</sup> CD16<sup>+</sup>), and intermediate monocytes (CD14<sup>+</sup> CD16<sup>+</sup>). Terminally  
155 differentiated/exhausted natural killer (NK) cell (CD56<sup>low</sup> CD16<sup>hi</sup> CD57<sup>hi</sup>) proportions also  
156 increased with age, as did activated CD4<sup>+</sup> T cells and central memory (CM) CD8<sup>+</sup> T cells (Fig.  
157 3b, c). In contrast, older adults had lower proportions of naïve CD8<sup>+</sup> T cells, naïve B cells, gamma-  
158 delta ( $\gamma\delta$ ) T cells, and plasmablasts (Fig. 3c). Finally, we found that the age-related differences in  
159 cell type frequencies were not affected by SARS-CoV-2 viral load (Supp. Fig. 4).



160

161 **Fig. 3: Aging alters immune cell populations during COVID-19.** (a) Uniform Manifold Approximation and Projection

162 (UMAP) plot highlighting blood cell types analyzed by CyTOF. (b) Bar plot depicting blood cell types that are upregulated

163 (red) or downregulated (blue) with age at Visit 1. “gd T cell” stands for  $\gamma\delta$  T cell. (c) Scatter plots depict centered log

164 ratio (CLR) transformed proportions of CD14+CD16+ monocytes and naive CD8 T cells as a function of age. P values

165 were calculated using linear modeling with Benjamini-Hochberg correction.

166

### 167 Age-dependent changes in PBMC gene expression at the time of hospitalization

168 Next, we performed PBMC transcriptional profiling and identified 3,763 genes significantly

169 associated with age at baseline (Visit 1), controlling for sex and disease severity (see Methods)

170 (adjusted  $P < 0.05$ , Fig. 4a). Gene set enrichment analysis (GSEA) revealed upregulation of



171 several innate immune-related pathways in older participants, including IFN- $\alpha/\beta$  and TLR  
172 cascades, as well as IFN- $\gamma$  signaling (Fig. 4b). In contrast, several adaptive immunity-related  
173 pathways were downregulated in older individuals, such as B cell receptor (BCR) signaling, T cell  
174 receptor (TCR) signaling, and PD1 signaling.

175

### 176 **Increased activation of type I interferon signaling in older adults**

177 Prior studies have demonstrated a direct relationship between SARS-CoV-2 viral load and  
178 IFN-stimulated gene (ISG) expression<sup>17,26</sup>. We therefore hypothesized that the strong positive  
179 correlation between age and viral load (Fig. 2e) might contribute to the upregulation of innate  
180 immunity genes and pathways that we observed in older adults. To test this hypothesis, we  
181 repeated the differential expression and GSEA analyses while controlling for SARS-CoV-2 viral  
182 load. Age-related increases in IFN- $\gamma$ , TLR signaling, and neutrophil degranulation remained  
183 significant. IFN- $\alpha/\beta$ , IL2, and caspase activation signaling, however, lost statistical significance,  
184 suggesting that the stronger activation of these pathways in older patients was due to the age-  
185 related increase in viral load.


186 To assess whether our observations were specific for COVID-19 or reflected general  
187 effects of aging, we compared our GSEA results against public data from 14,983 healthy adults  
188 across the age spectrum<sup>5</sup>. While we observed age-related upregulation of some pathways (e.g.,  
189 IFN- $\gamma$  and TLR signaling) in both our data and the healthy controls (Supp. Fig. 5a), other pathways  
190 were uniquely upregulated in the context of COVID-19 (e.g., caspase activation, TRAF6-mediated  
191 IRF7 activation) (Supp. Data 3). Similarly, age-related downregulation of TCR and BCR signaling,  
192 as well as several other pathways, was unique to COVID-19 (Supp. Fig. 5b).

193

### 194 **Age-dependent differences in the longitudinal dynamics of PBMC gene expression**

195           We next performed a longitudinal analysis of PBMC transcriptomics data over 28 days  
196 following hospital admission to identify genes that exhibited age-dependent differences in  
197 temporal dynamics, while controlling for participants' sex and severity trajectory group. Using  
198 linear mixed effects modeling, we identified 2,737 genes that had different longitudinal dynamics  
199 across age quintiles (Fig. 4c, Supp. Data 5). Several groups of genes demonstrated marked  
200 differences in expression dynamics. For example, the expression of MHC class II genes (e.g.,  
201 *HLA-DRA*) increased over time post-hospitalization in all age groups, but the rate of increase was  
202 greater in younger participants (Fig. 4d, e, Supp. Fig. 6). In contrast, the expression of MHC class  
203 I genes (e.g., *HLA-A*) decreased over time across all five age groups, but the rate of decrease  
204 was greater in older participants. TCR signaling genes (e.g., *CD3E*, *LAT*) were globally  
205 upregulated over time, however their induction was notably attenuated in the oldest versus  
206 youngest age quintiles.

207           The longitudinal dynamics of several canonical inflammatory genes also differed between  
208 age groups. For instance, the expression of *CXCL6* increased over the course of hospitalization  
209 in the oldest age group, while in younger participants its expression decreased markedly. In  
210 contrast, expression of the anti-inflammatory gene *IL10RA* in the youngest participants increased  
211 over time to a much greater extent compared to the oldest participants, suggesting both greater  
212 activation and impaired attenuation of immune signaling with advanced age.



214 **Fig. 4: Aging leads to changes in PBMC gene expression during COVID-19.** (a) Volcano plot highlighting genes  
215 associated with age at Visit 1 in PBMC RNA-seq data. (b) Plot demonstrating the normalized enrichment score of select  
216 Reactome pathways associated with age at Visit 1, with and without controlling for viral load, in PBMC samples. (Full  
217 results are tabulated in Supp. Data 1 and 2.) P values in (a, b) were calculated with limma's linear model and Benjamini-  
218 Hochberg correction. (c) Heatmap representing the temporal slopes (i.e., change in gene expression per 1 day) of  
219 2,812 genes that differ longitudinally between the 5 age groups (adjusted  $P < 0.05$ ). (d) Heatmaps representing the  
220 temporal slopes of select MHC, inflammatory, and TCR signaling genes from (c). (e) Plots demonstrating the temporal  
221 dynamics of 6 example genes from (g). P values were calculated using linear mixed effects modeling and Benjamini-  
222 Hochberg correction. (Full temporal dynamics plots with confidence intervals are provided in Supp. Fig. 6.)  
223

## 224 **Age-dependent differences in cytokine and chemokine levels upon hospitalization and** 225 **over time**


226 The impact of aging on immune signaling in COVID-19 was also evident at the protein  
227 level. Analysis of proximity extension assay (Olink) protein data from serum samples identified 43  
228 proteins that significantly correlated with age at the time of hospital admission (Fig. 5a, b, Supp.  
229 Fig. 7a). Of these, 31 increased with age, and the protein with the greatest effect size was CXCL9,  
230 a T-cell chemoattractant induced by IFN- $\gamma$  and produced by neutrophils and macrophages<sup>6</sup>.  
231 Twelve proteins significantly decreased with age, including TNFSF11, which is involved in the  
232 regulation of T cell-dependent immune responses and group 2 innate lymphoid cell-mediated type  
233 2 immunity<sup>27</sup>, and SIRT2, which may attenuate aging-associated inflammation through de-  
234 acetylation of the NLRP3 inflammasome<sup>28</sup>.

235 Based on prior work<sup>17</sup>, we hypothesized that aging might affect the relationship between  
236 protein expression and viral load. Consistent with this idea, we identified eight cytokines and  
237 chemokines whose expression levels correlated with SARS-CoV-2 viral load (Fig. 5c), and  
238 observed differences in this relationship between the oldest and youngest age groups. For  
239 instance, expression of IL10, a key anti-inflammatory cytokine, increased more strongly in

240 younger versus older adults in response to viral load. CX3CL1, a chemoattractant of T cells and  
 241 monocytes, exhibited a similar relationship (Fig. 5c).

242 We next evaluated the longitudinal dynamics of cytokine/chemokine expression in the  
 243 serum after hospitalization (Fig. 5d). The expression of several cytokines, such as TNFSF11,  
 244 increased steeply over time in younger adults but lagged in the oldest adults (Fig. 5e, Supp. Fig.  
 245 7b). Conversely, the expression of several proinflammatory cytokines and chemokines such as  
 246 CXCL8, CXCL9 and IL6 decreased rapidly over time in younger adults, while in the oldest adults  
 247 expression increased over time (CXCL8, CXCL9) or declined more slowly (IL6) (Fig. 5e).

248



249 **Fig. 5: Aging leads to differences in cytokine and chemokine levels during COVID-19.** (a) Bar plot highlighting  
 250 proteins that are upregulated (red) or downregulated (blue) with age at Visit 1 (adjusted P < 0.05). (b) Scatter plots of  
 251 the normalized protein expression (NPX) of representative proteins, CXCL9 and SIRT2, as a function of age. P values  
 252

253 are calculated using linear regression and Benjamini-Hochberg correction. (c) Dot plot representing the slope of  
254 cytokine expression versus viral load in the youngest and oldest age quintiles, [18,46] and [71,96], respectively. (d)  
255 Heatmap depicting temporal slopes (i.e., change in protein expression per 1 day) of all cytokines that display age-  
256 dependent longitudinal dynamics (adjusted  $P < 0.05$ ). (e) Plots showing the temporal dynamics of 4 example cytokines  
257 from (d). P values in (d, e) are calculated using linear mixed effects modeling and Benjamini-Hochberg correction.

## 258 259 **Age-dependent changes in respiratory tract gene expression and the airway microbiome**


260 We next asked whether aging was associated with changes in host gene expression and  
261 the upper airway microbiome (including virome) using nasal swab metatranscriptomics. We  
262 identified 913 host genes that were significantly associated with age (Fig. 6a), representing  
263 several key immune signaling pathways (Fig. 6b). TLR signaling, which plays an important role in  
264 microbial recognition, was upregulated with age, as were genes related to IFN- $\alpha/\beta$ , IL1, IL4, IL13,  
265 IL10, IL17, and caspase activation signaling. In contrast, T cell-related pathways (TCR signaling,  
266 co-stimulation by the CD28 family, and PD1 signaling) were downregulated with age, similar to  
267 our observations in peripheral blood. *In silico* prediction of upstream cytokine activation states  
268 demonstrated age-related activation of TNF, IL6, IFN- $\gamma$ , IL1A/B, IL22 and CSF1 (Fig. 6c).

269 Our study design enabled assessment of inflammatory pathways across anatomic  
270 compartments. Thus, we were interested in the extent to which gene expression in the blood and  
271 the upper respiratory tract was coordinated. To this end, we calculated the Pearson's correlation  
272 coefficients of gene expression between matched PBMC and nasal samples in the youngest  
273 group, and separately in the oldest group. We found 52 genes that had relatively high correlation  
274 coefficients in both groups, in particular those related to type I IFN signaling (e.g., *IFI6*, *IFI44*,  
275 *IFIT3*) and antigen presentation (HLA genes) (Fig. 6d).

276 As TLR pathways in the airway were strongly upregulated with age, we asked whether  
277 this could be due to differences in SARS-CoV-2 viral load and/or the nasal microbiome. We found  
278 that at Visit 1, the total bacterial load correlated with both ISG and TLR gene expression, while  
279 SARS-CoV-2 viral load only correlated with ISG expression (Fig. 6e). We thus considered whether

280 variations in bacterial load across the age span might explain the observed age-related TLR  
281 signaling differences, however no variation was found (Supp. Fig. 8).

282 We also considered whether age-related differences in specific taxa within the airway  
283 microbiome might contribute to the aforementioned differences in TLR signaling.  
284 Metatranscriptomic analysis identified only one significant genus, *Lawsonella*, whose abundance  
285 decreased with age (Fig. 6f). *Lawsonella* abundance positively correlated with TLR gene  
286 expression across all age groups, however, demonstrating that it did not account for the age-  
287 related upregulation in TLR signaling (Fig. 6g). Lastly, we evaluated the upper respiratory tract  
288 virome, and observed reactivation of herpes simplex virus and cytomegalovirus over the course  
289 of hospitalization in the oldest age quintile, but not in younger participants (Fig. 6h). This  
290 suggested that older adults may have less capacity to maintain innate immune control of latent  
291 viral infections.



292  
 293 **Fig. 6: Aging changes upper respiratory tract gene expression and the airway microbiome in COVID-19.** (a)  
 294 Volcano plot depicting genes associated with age at Visit 1 in nasal swab metatranscriptomics data. (b) Normalized  
 295 enrichment scores of select Reactome pathways associated with age at Visit 1, with (right) and without (left) controlling  
 296 for viral load, in nasal samples. (c) Bar plot depicting cytokines predicted by Ingenuity Pathway Analysis to be  
 297 upregulated with age in nasal samples. (d) Scatter plot depicting the Pearson's correlation coefficient of gene  
 16



298 expression between PBMC and nasal samples. Each dot indicates the correlation coefficient between PBMC  
299 expression and nasal expression of a gene, in the youngest (x-axis) and oldest (y-axis) age group. The black dots mark  
300 the genes with correlation coefficients  $> 0.5$  in both age groups ( $n = 52$  genes). (e) Dot plot highlighting correlations  
301 between SARS-CoV-2 viral load (log-transformed reads per million (rpM)), total bacterial abundance (log-transformed  
302 rpM), interferon stimulated gene (ISG) expression score and Toll like receptor (TLR) gene expression score. (f) Relative  
303 abundance of *Lawsonella* (rpM) across the age quintiles. In (f, g), P values were calculated with one-way ANOVA test.  
304 (g) Correlation between *Lawsonella* relative abundance and TLR gene expression across the age quintiles. P values  
305 were calculated using the test of association with Pearson's correlation coefficient and adjusted with Benjamini-  
306 Hochberg correction. (h) Percentages of cases with herpes simplex virus (HSV) or cytomegalovirus (CMV) transcript  
307 detection in the youngest versus oldest age quintiles. The number on top of each bar indicates the number of positive  
308 cases over the number of total samples. P-values were calculated by Fisher exact test.

309


### 310 **Relationships between aging, immune response, and COVID-19 severity**

311 Previous studies have established that severe COVID-19 involves a dysregulated host  
312 response characterized by inappropriate activation of inflammatory and immunoregulatory  
313 pathways<sup>29-31</sup>. We therefore sought to examine the intersection of aging, COVID-19 severity, and  
314 host immune responses by assessing PBMC gene expression differences at Visit 1 between  
315 participants with mild/moderate (baseline respiratory severity ordinal scale<sup>2</sup> (OS) 3-4) and severe  
316 (baseline OS 5-6) COVID-19, within the youngest and oldest age groups (Fig. 7a).

317 Several immune signaling pathways were associated with disease severity in an age-  
318 dependent manner. For example, only in the oldest age quintile was severe COVID-19 associated  
319 with upregulation of IL3, IL5 and GM-CSF, IL4 and IL13, TLR, and NRLP3 inflammasome  
320 signaling pathways in the upper airway. Similarly in the blood, we found that the IL1 signaling  
321 pathway was only upregulated in severe COVID-19 in the oldest adults. We also identified several  
322 pathways that associated with COVID-19 severity independent of age. For example, in PBMCs  
323 from both the youngest and oldest participants, severe disease was associated with upregulation  
324 of neutrophil degranulation genes, and downregulation of pathways related to TCR, IFN- $\alpha/\beta$ , IFN-  
325  $\gamma$ , IL2 and PD1 signaling.

326           Assessment at the protein level provided further insights regarding the immunological  
327 intersection of aging and COVID-19 severity (Fig. 7b). Notably, we found that the expression of  
328 several canonical proinflammatory cytokines and chemokines, such as IL6, oncostatin M (OSM),  
329 CXCL8 and CXCL9, was uniquely upregulated with disease severity in the oldest adults.  
330 Increased expression of the anti-inflammatory cytokines TGF- $\beta$ 1 and IL10 in severe disease was  
331 also specific to the oldest age quintile. Serum concentrations of several other proteins increased  
332 in severe disease independent of age, including CCL7, a leukocyte chemoattractant<sup>32</sup>, S100A12,  
333 a neutrophil-derived cytosolic pro-inflammatory protein<sup>33</sup>, and CD274 (PDL1), an immune  
334 checkpoint inhibitor. Similarly, we found that severity was associated with reduced expression of  
335 several cytokines regardless of age, including IL12B and LTA (TNF- $\beta$ ). We tested whether the  
336 differences in SARS-CoV-2 viral load could significantly influence the results, and found that they  
337 did not (Supp. Fig. 9).

338           Finally, we asked whether anti-IFN- $\alpha$  autoAb prevalence was associated with aging and  
339 COVID-19 severity. We found a significant positive correlation between age and anti-IFN- $\alpha$   
340 autoAb prevalence at Visit 1 (Fig. 7c), and a greater prevalence of the autoAbs in participants  
341 with severe disease (Fig. 7d). The presence of anti-IFN- $\alpha$  autoAbs was also associated with  
342 impaired ISG expression (Supp. Fig. 10).




343  
 344 **Fig. 7: Aging and COVID-19 severity.** (a, b) Dot plots highlighting a) select Reactome pathways in PBMC or nasal  
 345 RNA-seq data, and b) serum proteins (Olink) that were upregulated in severe participants (baseline respiratory severity  
 346 ordinal scale 5-6) compared to mild/moderate (ordinal scale 3-4) participants at Visit 1, stratified by age group (youngest  
 347 or oldest). P values in (a, b) were calculated with linear modeling and Benjamini-Hochberg correction. (c) Box plot  
 348 demonstrating association between age and presence of anti-IFN- $\alpha$  autoAbs in the 835 participants with available  
 349 autoAb data at Visit 1. P value was calculated with the Wilcoxon rank-sum test. (d) Bar plot demonstrating the  
 350 percentage of severe and mild/moderate participants who had anti-IFN- $\alpha$  antibodies (9/542 participants, 1.66% in  
 351 mild/moderate; 20/293 participants, 6.83% in severe). P-value was calculated using the Chi-squared test.

352

353 **Integrated analysis of protein and transcriptomics data**

354 Finally, we sought to integrate findings across genes and proteins, and between the blood  
355 and airway compartments. Integrated network analysis of statistically significant age-associated  
356 proteins and age-associated genes from the blood identified three prominent nodes related to  
357 chemokine ligand (CCL) signaling, T cell signaling and the cell cycle (Fig. 8a, see Methods).  
358 Additionally, analysis of the ten most significant proteins and their immediately downstream genes  
359 illuminated the complex cross talk between several key immune mediators. For example, CXCL9  
360 activates the genes *CXCR3* and *CXCR5*, and inhibits the gene *DPP4* (also known as *CD26*),  
361 which is upregulated on T cells after activation<sup>34</sup> (Supp. Fig. 11). Of these, CXCL9 was positively  
362 associated with age, while the three downstream genes were negatively correlated with age.

363 To investigate how aging could potentially affect ligand-receptor interactions in both the  
364 blood and airway, we studied ligands in our protein data that were significantly associated with  
365 age at Visit 1, and examined the expression of the genes that encoded their cognate receptors.  
366 This analysis further highlighted transcriptomic/proteomic concordance and discordance (Fig. 8b).  
367 For example, aging was associated with increased expression of serum CXCL9 and CCL11, but  
368 decreased expression of *DPP4*, which encodes a receptor for these ligands. In contrast, the  
369 expression of both TNF ligand and its receptors (e.g., *TNFRSF1A*, *TNFRSF1B*, *LTBR*) were  
370 positively associated with age.



371  
 372  
 373 **Fig. 8: Integrated network analysis of serum cytokine/chemokine and PBMC and nasal transcriptomic data. (a)**  
 374 Network analysis of serum cytokines and PBMC genes significantly associated with age at Visit 1 using protein-protein  
 375 interactions reported in Omnipath. (b) Analysis of ligand-receptor interactions from cytokine data, PBMC and nasal  
 376 RNA-seq data. The inner most ring shows the significant cytokines from Visit 1 analysis and their magnitude of their  
 377 average change per 1 year of age. The two outer rings illustrated genes that encode known receptors for each cytokine  
 378 and their associated change per one year of age. P values for the cytokines were calculated using linear models and  
 379 Benjamini-Hochberg correction. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001.

380

381 **Discussion:**

382 An effective host response to viral infection depends on potent early innate immune  
383 activation, engagement of adaptive immune effectors, and then, upon effective viral clearance,  
384 attenuation of this inflammatory signaling to prevent excessive tissue and pathologic  
385 consequences<sup>35</sup>. We observed age-dependent dysregulation of this program at the  
386 transcriptional, protein and cellular levels, manifesting in an imbalance of inflammatory responses  
387 over the course of hospitalization. Our results identify discrete innate and adaptive immune  
388 signaling pathways which are altered with age, suggesting potential targets for therapeutic  
389 intervention.

390 The role of type I IFN signaling in age-related immune dysregulation during COVID-19 has  
391 remained unclear, with some reports suggesting impaired induction of ISGs<sup>7,15,24</sup> and others  
392 demonstrating the contrary<sup>12,25</sup>. We found that older age was associated with increased type I IFN  
393 signaling in both the blood and respiratory tract, but that the relationship was principally driven by  
394 differences in SARS-CoV-2 viral load. In contrast, IFN- $\gamma$  signaling, which is associated with poor  
395 prognosis in COVID-19 participants<sup>36</sup>, was significantly upregulated with age independent of viral  
396 load.

397 Several factors likely contribute to higher SARS-CoV-2 viral loads in older adults, including  
398 impaired T and B cell immunity and impaired MHC antigen presentation, each of which we  
399 observed at the transcriptional, protein and cellular levels in our dataset. Delayed viral clearance  
400 due to these age-related factors could facilitate the evolution of novel SARS-CoV-2 variants<sup>37,38</sup>.  
401 Therefore, it is possible that coronavirus evolution could occur inside the host to a greater extent  
402 in older adults compared to the young, although our study was not designed to test this possibility.

403 Older adults had lower proportions of naïve CD8+ T cells and  $\gamma\delta$  T cells, which contribute  
404 to effective clearance of viral pathogens<sup>24,39,40</sup>. Terminally differentiated/exhausted NK cells,  
405 which are associated with severe COVID-19<sup>41</sup>, were more prevalent in older adults, as previously

406 observed<sup>12</sup>, as were central memory CD8+ T cells. Impaired T cell signaling in older adults was  
407 also observed at the transcriptional level in both the blood and the upper respiratory tract upon  
408 hospitalization. Longitudinal analyses demonstrated attenuated expression dynamics of TCR  
409 signaling-related genes in the older participants' blood samples (Fig. 3g, h). We also observed  
410 differences in the relationship between viral load and cytokines important for T cell recruitment in  
411 the oldest versus youngest adults, such as the chemokine CX3CL1.

412 Younger adults exhibited a much more robust induction of MHC II gene expression over  
413 the course of hospitalization. This is consistent with a previous study that reported *HLA-DR*  
414 expression increases over time following symptom onset in young COVID-19 participants, but not  
415 in older ones<sup>12</sup>. We also found that expression of MHC I genes decreased more rapidly post-  
416 hospitalization in the oldest versus the youngest adults. Given that SARS-CoV-2 can subvert  
417 immune responses by reducing MHC I surface levels in infected cells<sup>42</sup>, our results suggest that  
418 older participants may be even more vulnerable to this viral immune evasion mechanism.

419 Evidence of impaired B cell immunity was also observed in the older participants,  
420 consistent with prior studies<sup>12,24</sup>. Age was associated with reduced expression of genes involved  
421 in BCR signaling at the time of hospitalization. Furthermore, we observed lower proportions of  
422 naïve B cells and plasmablasts in the oldest adults. Functional ramifications of this were evident  
423 in decreased anti-SARS-CoV-2 RBD Ab levels, both upon hospitalization and when assessed  
424 longitudinally over 28 days.

425 Effective modulation of inflammatory responses is critical for restoration of immune  
426 homeostasis and mitigation of excessive tissue damage. We found consistent evidence of  
427 prolonged, potentially pathologic inflammatory responses in the oldest adults from transcriptomic  
428 and proteomic analyses. For instance, upon hospitalization, proinflammatory cytokines such as  
429 TNF, IL6, CXCL8, and CXCL9 were higher in the older participants, and continued to increase  
430 over time. In contrast, these cytokines decreased over time in the younger participants. Our  
431 results suggest that age-related changes may exacerbate the overexuberant inflammatory

432 signaling in severe COVID-19, an early hypothesis<sup>12,24</sup> that has not yet been validated in a large  
433 observational cohort.

434 The oldest adults in our cohort had evidence of HSV and CMV reactivation in the airway  
435 over the first 28 days after hospitalization. This may reflect impaired antiviral immune defenses in  
436 older adults exacerbated in the context of SARS-CoV-2 challenge. Furthermore, reactivation of  
437 latent Herpesviridae may contribute to excessive inflammatory responses observed in the older  
438 adults, as has been described in participants with human immunodeficiency virus (HIV)  
439 infection<sup>43</sup>.

440 Advanced age was also associated with upregulation of TLR signaling genes in both the  
441 airway and the blood, independent of SARS-CoV-2 viral load (Fig. 3e, 5b). We found that airway  
442 bacterial load correlated with TLR expression independent of age, and compositional differences  
443 in the microbiome across age groups did not explain this association, suggesting that age-related  
444 increases in TLR gene expression were caused by microbe-independent factors. Consistent with  
445 this idea are studies demonstrating that upregulation of innate immune receptors, including TLRs,  
446 could be an intrinsic feature of inflammaging<sup>24,44</sup>.

447 Severe COVID-19 is characterized by dysregulated, pathologic inflammatory  
448 responses<sup>29,45,46</sup>. We found that aging was associated with higher expression of several signaling  
449 pathways previously implicated in this pathologic immune dysregulation. For instance, in the  
450 oldest adults, severe COVID-19 was uniquely associated with impaired systemic Type 1 T helper  
451 cell (IL2, GM-CSF) and Type 2 T helper cell (IL5) responses, juxtaposed against hyperactivation  
452 of proinflammatory cytokines such as IL6, OSM, CXCL8, and CXCL9. In the airway, severe  
453 COVID-19 in the oldest age group led to greater NLRP3 inflammasome and TLR activation  
454 compared to the youngest group. These differences raise the possibility that older adults with  
455 severe COVID-19 may respond differently, and perhaps more favorably, to immunomodulatory  
456 therapies directed at certain inflammatory cytokines.



457 We also found that many features of severity-associated immune dysregulation were  
458 conserved across the lifespan, including an impairment in type I IFN signaling in severe disease.  
459 While presence of anti-IFN- $\alpha$  autoAbs was associated with impaired ISG expression and  
460 increased COVID-19 severity, they were detected in < 7% of adults in the oldest age quintile,  
461 suggesting a potentially important, but overall limited contribution to aging-associated COVID-19  
462 severity relative to other immunological factors.

463 Our study is the largest molecular assessment of aging and COVID-19 to date (n = 1,031  
464 participants at 20 hospitals across the United States), and one of the few to perform an integrated  
465 assessment of both immune and microbial features, allowing for identification of aging-related  
466 changes at a scale not previously achieved. We conducted multiomic, host/microbe systems  
467 immunoprofiling to assess the longitudinal dynamics of immune responses at the cellular,  
468 transcriptional and protein level in both the blood and airway. In addition, we add to the COVID-  
469 19 aging literature by integrating immunological analyses with assessment of both viral and  
470 microbiome dynamics over the course of hospitalization.

471 Our findings may have implications for age-specific COVID-19 therapeutic approaches.  
472 For example, a longer duration of antiviral therapy in older adults may be needed to achieve  
473 sufficient viral clearance for infection resolution compared to younger participants, and  
474 immunotherapy regimens may be particularly beneficial in older age, given impaired B cell  
475 responses. In addition, the optimal timing and use of immunomodulatory therapies (such as  
476 corticosteroids) may differ across the age spectrum, given the need to maximize control of  
477 inflammation without compromising the immune response to infection<sup>47,48</sup>.

478 Limitations of our study include the lack of a concurrently enrolled SARS-CoV-2-negative  
479 control group, and the lack of a non-hospitalized COVID-19 group. To partially address the first  
480 limitation, we analyzed publicly available gene expression datasets to incorporate findings from  
481 unrelated, healthy cohorts<sup>5</sup>. Participants in our current study were enrolled prior to the introduction  
482 of SARS-CoV-2 vaccines, and age-related differences in host immune responses may differ from

483 a contemporary cohort due to variation in both vaccination status and the circulating SARS-CoV-  
484 2 variants. While this aspect limits extrapolation of our findings to immunized older adults, the  
485 naïve state of our study population was also a strength, as our results are not confounded by prior  
486 vaccination or infection, providing a window into age-related differences in immune response to  
487 a novel emerging viral respiratory pathogen.

488 In summary, we find that aging has marked impacts on host immune and viral dynamics  
489 in both recognized and novel ways in hospitalized participants with COVID-19. Notably, older  
490 adults exhibited impaired viral clearance, dysregulated immune signaling, and persistent and  
491 presumably pathologic activation of proinflammatory genes and cytokines.

492 **Materials and methods:**

493 **Patient enrollment and sample collection**

494 This study leveraged data from the IMPACC cohort<sup>2,23</sup>, which enrolled participants from  
495 20 hospitals across 15 medical centers in the United States between May 5th, 2020 and March  
496 19th, 2021. Eligible participants were participants hospitalized with SARS-CoV-2 infection  
497 confirmed by RT-PCR and symptoms or signs consistent with COVID-19. The detailed study  
498 design and schedule for clinical data and biologic sample collection, and shared core platform  
499 assessments were previously described<sup>23,30</sup>. Detailed clinical assessments and sampling of blood  
500 and upper respiratory tract were performed within approximately 72 hours of hospitalization (Visit  
501 1), and on approximately Days 4, 7, 14, 21, 28 after hospital admission. As previously described<sup>23</sup>,  
502 biological sample collection and processing followed a standard protocol utilized by every  
503 participating academic institution.

504

505 **Ethics**

506 NIAID staff conferred with the Department of Health and Human Services Office for  
507 Human Research Protections (OHRP) regarding potential applicability of the public health  
508 surveillance exception [45CFR46.102(l)(2)] to the IMPACC study protocol. OHRP concurred that  
509 the study satisfied criteria for the public health surveillance exception, and the IMPACC study  
510 team sent the study protocol, and participant information sheet for review, and assessment to  
511 institutional review boards (IRBs) at participating institutions. Twelve institutions elected to  
512 conduct the study as public health surveillance, while three sites with prior IRB-approved  
513 biobanking protocols elected to integrate and conduct IMPACC under their institutional protocols  
514 (University of Texas at Austin, IRB 2020-04-0117; University of California San Francisco, IRB 20-  
515 30497; Case Western reserve university, IRB STUDY20200573) with informed consent  
516 requirements. Participants enrolled under the public health surveillance exclusion were provided  
517 information sheets describing the study, samples to be collected, and plans for data de-

518 identification, and use. Those that requested not to participate after reviewing the information  
519 sheet were not enrolled. In addition, participants did not receive compensation for study  
520 participation while inpatient, and subsequently were offered compensation during outpatient  
521 follow-ups.

522

### 523 **Common statistical analyses framework**

524 All raw data was obtained from the IMPACC study and are publicly available<sup>2,23</sup>. QC was  
525 performed by the IMPACC study as previously reported<sup>2,23</sup>. All data analyses were done in R  
526 v4.0.2. For each data type, we investigated the behavior of features both at Visit 1 (within 72  
527 hours of hospital admission for most of the participants) and longitudinally for scheduled visits  
528 (Visits 1-6, up to 30 days post-hospital admission, both inpatient and outpatient samples, and  
529 excluding escalation samples). For Visit 1 analyses, we used linear modeling with age as a  
530 continuous variable and controlled for sex and baseline respiratory severity. Severity was  
531 assessed using a previously described 7-point severity ordinal scale (OS) based on degree of  
532 respiratory illness at the time of sampling<sup>2</sup>.

533 In the longitudinal analyses, we used age quintiles ([18,46], [47,54], [55,62], [63,70] and  
534 [71,96]), and controlled for sex and disease severity trajectory group (TG), a previously defined  
535 metric of COVID-19 severity over time. Clinical trajectory groups were previously identified and  
536 assigned to all participants in this study<sup>2</sup>. For longitudinal analysis of SARS-CoV-2 nasal viral load  
537 and serum anti-Spike IgG, we used generalized additive models with mixed effects from the  
538 package gamm4 (v0.2.6) to evaluate the effects of age while controlling for sex and TG.  
539 Generalized additive modeling was preferred for these features due to their non-linear trajectories  
540 as previously reported. For all other data types, we used linear mixed effects models from the  
541 package lme4 (v1.1.25). P values in all analyses were adjusted with Benjamini-Hochberg  
542 correction.

543

## 544 **Analysis of nasal metagenomics data**

545 Taxonomic alignments from nasal metagenomics data were obtained from raw fastq files  
546 using the CZ-ID pipeline<sup>49</sup>, which first removes human sequences via subtractive alignment  
547 against human genome build 38, followed by quality and complexity filtering. Subsequently,  
548 reference-based taxonomic alignment at both the nucleotide and amino acid levels against  
549 sequences in the National Center for Biotechnology Information (NCBI) nucleotide (NT) and non-  
550 redundant (NR) databases, respectively, is carried out, followed by assembly of the reads  
551 matching each taxon. Taxa were aggregated to the genus level for analyses. For all analyses  
552 using SARS-CoV-2 viral load, log transformation of total reads per million (rpM) aligned to the  
553 Beta-coronavirus genus was used.

554

## 555 **Analysis of SARS-CoV-2 antibody titers**

556 Antibody levels against the recombinant SARS-CoV-2 spike protein receptor-binding  
557 domain (RBD) were measured using a research-grade enzyme-linked immunosorbent assay  
558 (ELISA) as described<sup>30</sup>. The optical density (OD) was measured and the area under the curve  
559 was calculated, considering 0.15 OD as the cutoff.

560 Longitudinal analysis of SARS-CoV-2 viral load was performed using the gamm4 function  
561 from the gamm4 package (v0.2.6), using the following formula:

562  $\text{viral\_load} \sim \text{s}(\text{event\_date}, \text{bs}="cr") + \text{s}(\text{event\_date}, \text{bs}="cr", \text{by}=\text{age\_group}) + \text{age\_group} +$   
563  $\text{trajectory\_group} + \text{sex}$

564 with random effects (1|site/pid). In the formula, viral\_load is the log-transformed rpM counts of  
565 SARS-CoV-2 as measured by nasal metatranscriptomics, event\_date was the number of days  
566 post hospitalization, age\_group was the participant's age quintile ([18,46], [47,54], [55,62],  
567 [63,70], [71,96]), TG was the participant's trajectory group, site was the participant's enrolment  
568 site and pid was the participant ID.

569

## 570 **Analysis of PBMC and nasal RNA-seq data**

571 PBMC and nasal RNA-seq libraries were sequenced on a NovaSeq 6000 (Illumina) at 100  
572 bp paired-end read length. The sequencing data was aligned using STAR aligner v2.4.2a and  
573 v.2.4.3<sup>50</sup> and GRCh38 reference genome (Ensembl releases 91 and 100). Gene count tables  
574 were generated using htseq-count v0.4.1 and v0.4.2<sup>51</sup>.

575 For all RNA-seq analyses, we retained protein-coding genes that had a minimum of 10  
576 counts in at least 20% of the samples. We normalized the gene counts using the voom function  
577 (normalize.method = "quantile") from the limma package v3.46.0<sup>52</sup>, fitted a linear model for the  
578 gene expression with lmFit function (default settings), calculated the empirical Bayes statistics  
579 with eBayes function (default settings), and calculated the P values for differential expression with  
580 Benjamini-Hochberg multiple comparison correction. For Visit 1 analyses, we controlled for sex  
581 and severity OS at Visit 1, as well as log-transformed viral load in certain analyses when indicated.  
582 *In silico* prediction of upstream cytokine activation was performed with Qiagen's Ingenuity  
583 Pathway Analysis software v01-21-03 (using default settings).

584 For the Visit 1 severity analysis, we defined mild/moderate participants as having baseline  
585 respiratory disease severity (OS) 3-4, and severe participants as having baseline OS 5-6, and  
586 limited to the youngest and oldest age quintiles. First, we normalized the gene counts with the  
587 voom function (normalize.method = "quantile"), and fitted a linear model for the gene expression  
588 using the lmFit function and the formula  $\sim 0 + \text{age\_severity} + \text{sex}$ , where age\_severity is the  
589 combined categorical variable of participants' ages (young,  $\leq 46$  years old, or old,  $\geq 71$  years old)  
590 and disease severity (mild or severe). With this parameterization, the age\_severity variable has  
591 4 levels: young\_mild, young\_severe, old\_mild, and old\_severe. To assess differences between  
592 severe and mild disease among young and old participants, we used the contrasts.fit function on  
593 the contrasts [young\_severe – young\_mild) and [old\_severe – old\_mild), respectively. Finally, we  
594 calculated the empirical Bayes statistics on the two contrasts with the eBayes function (default

595 settings), and calculated the P values for differential expression with Benjamini-Hochberg  
596 correction.

597 For the longitudinal analysis, we restricted to hospitalized and outpatient samples that  
598 were collected up to 30 days post hospitalization, excluding samples collected during care  
599 escalation. We retained protein-coding genes with at least 10 counts in at least 20% of samples.  
600 Next, we normalized the gene counts using the voom function without adding any covariates, and  
601 modelled the normalized gene expression using linear mixed effects (LME) model with the lmer  
602 function from the lme4 package v1.1.25. Our LME model's formula was:

603  $gene_i \sim event\_date + age\_group + event\_date:age\_group + sex + TG + (1|pid)$   
604 (1)

605 where  $gene_i$  was the normalized expression of gene  $i$ .

606 To calculate the P value of the interaction term between `event_date` and `age_group`, we  
607 used the `anova` function (`test = "LRT"`) to perform a likelihood ratio test between the model (1)  
608 above and the null model:

609  $gene_i \sim event\_date + age\_group + sex + TG + (1|pid)$   
610 (2)

611 The P values from the likelihood ratio tests were then adjusted with Benjamini-Hochberg  
612 correction.

613 Significant genes from the longitudinal analysis of PBMC RNA-seq data were clustered  
614 with the `pheatmap` package v1.0.12, using the Euclidean distance metric and the Ward's linkage  
615 (`clustering_method = "ward.D2"`). The TCR signaling genes and inflammatory genes were  
616 obtained from the corresponding Reactome and Hallmark pathways, respectively.

617

## 618 **Analysis of CyTOF data**

619 Blood samples were quantified on the Fluidigm Helios mass cytometer, and the cell types  
620 were annotated using an automated annotation pipeline<sup>30</sup>. Prior to analysis, we removed cells

621 identified as multiplets, debris, and those that were not identifiable with high confidence. Next,  
622 because neutrophils (CD16<sup>hi</sup>) were much more abundant than the other cell types (median 60%  
623 of all detected cells), they were also removed. Then, we normalized the cell type abundance for  
624 each participant by calculating the percentage of each cell type, adding a pseudocount of 1 to  
625 avoid taking the logarithm of zeros (the pseudocount is added even if the percentage is higher  
626 than zero), and computing its centered log ratio (CLR):

$$627 \quad CLR(X'_i) = \log\left(\frac{X'_i}{g(X'_i)}\right)$$

628 where log is the natural logarithm, and  $X'_i$  is the percentage of the cell type  $i$ :

$$629 \quad X'_i = \frac{X_i}{\sum X_i} \times 100 + 1$$

630 where  $X_i$  is the number of cells of cell type  $i$  in a participant.

631 For the Visit 1 analysis, we used a linear model to regress each cell type's CLR-  
632 transformed abundance on age, while controlling for sex and OS. For the longitudinal analysis,  
633 we used a linear mixed effect model to model the CLR-transformed abundance. The formulae for  
634 the full and null models are identical to equations (1) and (2).

635

### 636 **Analysis of serum inflammatory protein (Olink) data**

637 All samples were processed with the Olink multiplex assay inflammatory panels (Olink  
638 Proteomics), according to the manufacturer's instructions and as previously described<sup>30</sup>. This  
639 inflammatory panel included 92 proteins associated with human inflammatory conditions. Target  
640 protein quantification was performed by real-time microfluidic qPCR via the Normalized Protein  
641 Expression (NPX) manager software. Data were normalized using internal controls in every  
642 sample, inter-plate control and negative controls, and correction factor and expressed as log2  
643 scale proportional to the protein concentration. For additional quality control, we set any NPX



644 measurements below the assay's limit of detection (LOD) to zero. Next, we excluded proteins that  
645 were detected in fewer than 20% of samples, resulting in 84 proteins for analysis.

646 For the Visit 1 analysis, we standardized the NPX values and modeled them with linear  
647 regression on participants' ages, controlling for sex and OS. For the severity analysis, we defined  
648 mild participants as baseline OS of 3-4, and severe participants as baseline OS of 5-6. We then  
649 set up two linear models, one for young participants ( $\leq 46$  years old) and one for old participants  
650 ( $\geq 71$  years old), to model the standardized NPX values on severity (mild or severe), while  
651 controlling for sex.

652 For the longitudinal analysis, we also standardized the NPX values, and used the LME  
653 models and the formulae in equations (1) and (2). Significant cytokines in the longitudinal analysis  
654 were clustered with the pheatmap package v1.0.12, using the Euclidean distance metric and the  
655 complete linkage. P values in all cytokine analyses were adjusted with Benjamini-Hochberg  
656 correction.

657

## 658 **Analysis of anti-IFN- $\alpha$ antibody presence and correlation with interferon-related gene** 659 **expression**

660 Samples were screened for anti-type I IFN autoAbs in a multiplex, particle-based assay  
661 as previously described<sup>30</sup>. Participant samples with a fluorescence intensity  $> 3$  standard  
662 deviations above a mean of 1099 healthy controls at the earliest timepoint received were  
663 considered positive for anti-IFN Abs ( $> 1310$  FI for IFN- $\alpha$ ). To assess whether presence of anti-  
664 IFN- $\alpha$  Abs correlated with changes in IFN-related gene expression, we assessed expression of  
665 genes present in the REACTOME pathway "interferon alpha beta signaling" obtained from gsea-  
666 msigdb.org. All genes were assessed by linear regression using the formula  $\text{lm}(\text{exp} \sim \text{anti\_IFNa}$   
667  $+ \text{age} + \text{sex} + \text{viral\_load})$ , where exp was the normalized gene expression from PBMC data,  
668 antiIFNa was a binary variable indicating presence or absence of anti-IFN- $\alpha$  Abs, and viral\_load

669 was the log-transformed viral load measured by SARS-CoV-2 rpM from the nasal metagenomics  
670 data. P values were adjusted with Benjamini-Hochberg correction.

671

## 672 **Integrated analysis of serum cytokine, PBMC RNA-seq and nasal RNA-seq data**

673 To integrate the serum cytokines/chemokines with the PBMC and nasal transcriptomic  
674 data, ligand/receptor pairs were retrieved from Omnipath, a database of known protein-protein  
675 interactions, using the R package OmnipathR to identify receptors and protein associates for  
676 ligands in the serum OLINK. The change per year of age was graphed for significant age-  
677 associated ligands in the serum OLINK and their respective receptors/interactive proteins for both  
678 transcriptomics using the R package ComplexHeatmap.

679

## 680 **List of Supplementary Materials:**

681 Supplementary Table 1. Clinical and demographic characteristics of the cohort at baseline (Visit  
682 1).

683 Supplementary Figure 1. Comparison of viral load as measured by nasal swab qPCR and nasal  
684 swab RNA-seq (metatranscriptomics).

685 Supplementary Figure 2. Time since symptom onset across age groups at Visit 1.

686 Supplementary Figure 3. Visit 1 analysis and longitudinal analysis of IgG levels.

687 Supplementary Figure 4. Visit 1 analysis of CyTOF data while controlling for viral load.

688 Supplementary Figure 5. Comparison of PBMC RNA-seq data from this study to healthy control  
689 datasets, with differential gene expression analyses performed using age as a continuous  
690 variable.

691 Supplementary Figure 6. Plots of the dynamics of 6 example genes in PBMC samples.

692 Supplementary Figure 7. Effect of SARS-CoV-2 viral load on age-cytokine relationship at Visit 1,  
693 and the dynamics of 4 example cytokines.

694 Supplementary Figure 8. Bacterial load (reads per million, rpM) versus age quintiles.

695 Supplementary Figure 9. Aging and COVID-19 severity, analyses controlled for viral load.

696 Supplementary Figure 10. Expression of interferon-related genes in patients with or without anti-  
697 IFN- $\alpha$  antibodies at Visit 1.

698 Supplementary Figure 11. Network analysis of the top 10 significant serum proteins and their  
699 receptors and downstream signaling.

700 Supplementary Table 2. Prevalence of viral cases by age quintile over time in the nasal virome.

701

## 702 **CONSORTIA**

### 703 **#The IMPACC Network**

704 **National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda,**  
705 **MD 20814, USA:** Patrice M. Becker, Alison D. Augustine, Steven M. Holland, Lindsey B. Rosen,  
706 Serena Lee, Tatyana Vaysman

707 **Clinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston**  
708 **Children's Hospital, Boston, MA 02115, USA:** Al Ozonoff, Joann Diray-Arce, Jing Chen, Alvin  
709 Kho, Carly E. Milliren, Annmarie Hoch, Ana C. Chang, Kerry McEnaney, Brenda Barton, Claudia  
710 Lentucci, Maimouna Murphy, Mehmet Saluvan, Tanzia Shaheen, Shanshan Liu, Caitlin Syphurs,  
711 Marisa Albert, Arash Nemati Hayati, Robert Bryant, James Abraham

712 **Benaroya Research Institute, University of Washington, Seattle, WA 98101, USA:** Matthew  
713 C. Altman, Naresh Doni Jayavelu, Scott Presnell, Bernard Kohr, Azlann Arnett

714 **La Jolla Institute for Immunology, La Jolla, CA 92037, USA:** Bjoern Peters, Randi Vita, Kerstin  
715 Westendorf

716 **Knocean Inc. Toronto, ON M6P 2T3, Canada:** James A. Overton

717 **Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston,**  
718 **MA 02115, USA:** Ofer Levy, Hanno Steen, Patrick van Zalm, Benoit Fatou, Kinga Smolen, Arthur  
719 Viode, Simon van Haren, Meenakshi Jha

720 **Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA:** Lindsey  
721 R. Baden, Kevin Mendez, Jessica Lasky-Su, Alexandra Tong, Rebecca Rooks  
722 **Metabolon Inc, Morrisville, NC 27560, USA:** Scott R. Hutton, Greg Michelotti, Kari Wong  
723 **Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH**  
724 **44106, USA:** Rafick-Pierre Sekaly, Slim Fourati, Grace A. McComsey, Paul Harris, Scott Sieg,  
725 Susan Pereira Ribeiro  
726 **Drexel University, Tower Health Hospital, Philadelphia, PA 19104, USA:** Charles B. Cairns,  
727 Elias K. Haddad, Michele A. Kutzler, Mariana Bernui, Gina Cusimano, Jennifer Connors, Kyra  
728 Woloszczuk, David Joyner, Carolyn Edwards, Edward Lin, Nataliya Melnyk, Debra L. Powell,  
729 James N. Kim, I. Michael Goonewardene, Brent Simmons, Cecilia M. Smith, Mark Martens, Brett  
730 Croen, Nicholas C. Semenza, Mathew R. Bell, Sara Furukawa, Renee McLin, George P Tegos,  
731 Brandon Rogowski, Nathan Mege, Kristen Ullring  
732 **MyOwnMed Inc., Bethesda, MD 20817, USA:** Vicki Seyfert-Margolis  
733 **Emory School of Medicine, Atlanta, GA 30322, USA:** Nadine Rouphael, Steven E. Bosinger,  
734 Arun K. Boddapati, Greg K. Tharp, Kathryn L. Pellegrini, Brandi Johnson, Bernadine Panganiban,  
735 Christopher Huerta, Evan J. Anderson, Hady Samaha, Jonathan Sevransky, Laurel Bristow,  
736 Elizabeth Beagle, David Cowan, Sydney Hamilton, Thomas Hodder  
737 **Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA:** Ana Fernandez-Sesma,  
738 Viviana Simon, Florian Krammer, Harm Van Bakel, Seunghee Kim-schulze, Ana Silvia Gonzalez-  
739 Reiche, Jingjing Qi, Brian Lee, Juan Manuel Carreño, Gagandeep Singh, Ariel Raskin, Johnstone  
740 Tcheou, Zain Khalil, Adriana van de Guchte, Keith Farrugia, Zenab Khan, Geoffrey Kelly, Komal  
741 Srivastava, Lily Eaker, Maria Carolina Bermúdez González, Lubbertus C.F. Mulder, Katherine  
742 Beach  
743 **Immunai Inc. New York, NY 10016, USA:** Adeeb Rahman  
744 **Oregon Health Sciences University, Portland, OR 97239, USA:** William B. Messer, Catherine  
745 L. Hough, Sarah Siegel, Peter Sullivan, Zhengchun Lu

746 **Stanford University School of Medicine, Palo Alto, CA 94305, USA:** Holden Maecker, Bali  
747 Pulendran, R. Kari C. Nadeau, Yael Rosenberg-Hasson, Michael Leipold, Natalia Sigal, Angela  
748 Rogers, Andrea Fernandez, Monali Manohar, Evan Do, Iris Chang

749 **David Geffen School of Medicine at the University of California Los Angeles, Los Angeles**  
750 **CA 90095, USA:** Elaine F. Reed, Joanna Schaeenman, Ramin Salehi-Rad, Adreanne M. Rivera,  
751 Harry C. Pickering, Subha Sen, David Elashoff, Dawn C. Ward

752 **University of California San Francisco, San Francisco, CA 94115, USA:** David J. Erle,  
753 Carolyn S. Calfee, Carolyn M. Hendrickson, Kirsten N. Kangelaris, Viet Nguyen, Deanna Lee,  
754 Suzanna Chak, Rajani Ghale, Ana Gonzalez, Alejandra Jauregui, Carolyn Leroux, Luz Torres  
755 Altamirano, Ahmad Sadeed Rashid, Andrew Willmore, Prescott G. Woodruff, Matthew F.  
756 Krummel, Sidney Carrillo, Alyssa Ward, Charles R. Langelier, Ravi Patel, Michael Wilson, Ravi  
757 Dandekar, Bonny Alvarenga, Jayant Rajan, Walter Eckalbar, Andrew W. Schroeder, Gabriela K.  
758 Fragiadakis, Alexandra Tsitsiklis, Eran Mick, Yanedth Sanchez Guerrero, Rajani Ghale, Christina  
759 Love, Lenka Maliskova, Michael Adkisson

760 **Yale School of Medicine, New Haven, CT 06510, USA:** David A. Hafler, Ruth R. Montgomery,  
761 Albert C. Shaw, Steven H. Kleinstein, Jeremy Gygi, Shrikant Pawar, Anna Konstorum, Ernie  
762 Chen, Chris Cotsapas, Xiaomei Wang, Leqi Xu, Charles Dela Cruz, Akiko Iwasaki, Subhasis  
763 Mohanty, Allison Nelson, Yujiao Zhao, Shelli Farhadian, Hiromitsu Asashima

764 **Yale School of Public Health, New Haven, CT 06510, USA:** Denise Esserman, Leying Guan,  
765 Anderson Brito, Jessica Rothman, Nathan Grubaugh, Albert I. Ko

766 **Baylor College of Medicine and the Center for Translational Research on Inflammatory**  
767 **Diseases, Houston, TX 77030, USA:** David B. Corry, Farrah Kheradmand, Li-Zhen Song, Ebony  
768 Nelson

769 **Oklahoma University Health Sciences Center, Oklahoma City, OK 73104, USA:** Jordan P.  
770 Metcalf, Nelson I Agudelo Higueta, Lauren Sinko, J. Leland Booth

771 **University of Arizona, Tucson AZ 85721, USA:** Monica Kraft, Chris Bime, Jarrod Mosier, Heidi  
772 Erickson, Ron Schunk, Hiroki Kimura, Michelle Conway  
773 **University of Florida, Gainesville, FL 32611, USA:** Mark A. Atkinson, Scott C. Brakenridge,  
774 Ricardo F. Ungaro, Brittany Roth Manning,  
775 **University of Florida, Jacksonville, FL 32218, USA:** Jordan Oberhaus, Faheem W. Guirgis,  
776 **University of South Florida, Tampa FL 33620, USA:** Brittney Borresen, Matthew L. Anderson  
777 **University of Texas, Austin, TX 78712, USA:** Lauren I. R. Ehrlich, Esther Melamed, Cole  
778 Maguire, Justin F. Rousseau, Kerin C. Hurley, Janelle N. Geltman, Nadia Siles, Jacob E. Rogers  
779

## 780 References and Notes:

- 781 1. O'Driscoll, M. *et al.* Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*  
782 **590**, 140–145 (2021).
- 783 2. Ozonoff, A. *et al.* Phenotypes of disease severity in a cohort of hospitalized COVID-19  
784 patients: Results from the IMPACC study. *EBioMedicine* **83**, 104208 (2022).
- 785 3. Wu, C. *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death  
786 in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern.*  
787 *Med.* (2020) doi:10.1001/jamainternmed.2020.0994.
- 788 4. United States Centers for Disease Control and Prevention. Risk for COVID-19 Infection,  
789 Hospitalization, and Death By Age Group. *Risk for COVID-19 Infection, Hospitalization, and*  
790 *Death By Age Group* [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html)  
791 [discovery/hospitalization-death-by-age.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html) (2022).
- 792 5. NABEC/UKBEC Consortium *et al.* The transcriptional landscape of age in human peripheral  
793 blood. *Nat. Commun.* **6**, 8570 (2015).
- 794 6. Sayed, N. *et al.* An inflammatory aging clock (iAge) based on deep learning tracks  
795 multimorbidity, immunosenescence, frailty and cardiovascular aging. *Nat. Aging* **1**, 598–615  
796 (2021).
- 797 7. Bartleson, J. M. *et al.* SARS-CoV-2, COVID-19 and the aging immune system. *Nat. Aging* **1**,  
798 769–782 (2021).
- 799 8. Hagan, T. *et al.* Transcriptional atlas of the human immune response to 13 vaccines reveals  
800 a common predictor of vaccine-induced antibody responses. *Nat. Immunol.* (2022)  
801 doi:10.1038/s41590-022-01328-6.
- 802 9. Parry, H. *et al.* Extended interval BNT162b2 vaccination enhances peak antibody  
803 generation. *Npj Vaccines* **7**, 14 (2022).
- 804 10. Saadat, S. *et al.* Binding and Neutralization Antibody Titers After a Single Vaccine Dose in  
805 Health Care Workers Previously Infected With SARS-CoV-2. *JAMA* **325**, 1467 (2021).
- 806 11. Filardi, B. A. *et al.* Age-dependent impairment in antibody responses elicited by a  
807 homologous CoronaVac booster dose. *Sci. Transl. Med.* **15**, eade6023 (2023).
- 808 12. Lewis, S. A. *et al.* Differential dynamics of peripheral immune responses to acute SARS-  
809 CoV-2 infection in older adults. *Nat. Aging* **1**, 1038–1052 (2021).
- 810 13. Shaw, A. C. *et al.* Dysregulation of human Toll-like receptor function in aging. *Ageing Res.*  
811 *Rev.* **10**, 346–353 (2011).
- 812 14. Kollmann, T. R., Levy, O., Montgomery, R. R. & Goriely, S. Innate Immune Function by Toll-  
813 like Receptors: Distinct Responses in Newborns and the Elderly. *Immunity* **37**, 771–783  
814 (2012).
- 815 15. Connors, J. *et al.* Aging alters antiviral signaling pathways resulting in functional impairment  
816 in innate immunity in response to pattern recognition receptor agonists. *GeroScience* **44**,  
817 2555–2572 (2022).
- 818 16. Metcalf, T. U. *et al.* Human Monocyte Subsets Are Transcriptionally and Functionally Altered  
819 in Aging in Response to Pattern Recognition Receptor Agonists. *J. Immunol. Baltim. Md*  
820 *1950* **199**, 1405–1417 (2017).
- 821 17. Mick, E. *et al.* Upper airway gene expression shows a more robust adaptive immune  
822 response to SARS-CoV-2 in children. *Nat. Commun.* **13**, 3937 (2022).
- 823 18. Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls early  
824 SARS-CoV-2 infection in children. *Nat. Biotechnol.* **40**, 319–324 (2022).
- 825 19. Bastard, P. *et al.* Autoantibodies against type I IFNs in patients with life-threatening COVID-  
826 19. *Science* **370**, eabd4585 (2020).
- 827 20. van der Wijst, M. G. P. *et al.* Type I interferon autoantibodies are associated with systemic  
828 immune alterations in patients with COVID-19. *Sci. Transl. Med.* **13**, eabh2624 (2021).

- 829 21. Langelier, C. *et al.* Integrating host response and unbiased microbe detection for lower  
830 respiratory tract infection diagnosis in critically ill adults. *Proc. Natl. Acad. Sci.* 201809700  
831 (2018) doi:10.1073/pnas.1809700115.
- 832 22. Kalantar, K. L. *et al.* Integrated host-microbe plasma metagenomics for sepsis diagnosis in  
833 a prospective cohort of critically ill adults. *Nat. Microbiol.* (2022) doi:10.1038/s41564-022-  
834 01237-2.
- 835 23. IMPACC Manuscript Writing Team & IMPACC Network Steering Committee.  
836 Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective  
837 longitudinal study. *Sci. Immunol.* **6**, eabf3733 (2021).
- 838 24. Bajaj, V. *et al.* Aging, Immunity, and COVID-19: How Age Influences the Host Immune  
839 Response to Coronavirus Infections? *Front. Physiol.* **11**, 571416 (2021).
- 840 25. Zheng, Y. *et al.* A human circulating immune cell landscape in aging and COVID-19. *Protein*  
841 *Cell* **11**, 740–770 (2020).
- 842 26. Mick, E. *et al.* Upper airway gene expression reveals suppressed immune responses to  
843 SARS-CoV-2 compared with other respiratory viruses. *Nat. Commun.* **11**, (2020).
- 844 27. Ogasawara, N. *et al.* Role of RANK-L as a potential inducer of ILC2-mediated type 2  
845 inflammation in chronic rhinosinusitis with nasal polyps. *Mucosal Immunol.* **13**, 86–95  
846 (2020).
- 847 28. He, M. *et al.* An Acetylation Switch of the NLRP3 Inflammasome Regulates Aging-  
848 Associated Chronic Inflammation and Insulin Resistance. *Cell Metab.* **31**, 580-591.e5  
849 (2020).
- 850 29. Sarma, A. *et al.* Tracheal aspirate RNA sequencing identifies distinct immunological  
851 features of COVID-19 ARDS. *Nat. Commun.* **12**, 5152 (2021).
- 852 30. Arce, Joann *et al.* Multi-omic longitudinal study reveals immune correlates of clinical course  
853 among hospitalized COVID-19 patients. *Cell Rep. Med.* (2023).
- 854 31. Blanco-Melo, D. *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of  
855 COVID-19. *Cell* **181**, 1036-1045.e9 (2020).
- 856 32. Cheng, J. W. *et al.* The role of CXCL12 and CCL7 chemokines in immune regulation,  
857 embryonic development, and tissue regeneration. *Cytokine* **69**, 277–283 (2014).
- 858 33. Meijer, B., Geary, R. B. & Day, A. S. The Role of S100A12 as a Systemic Marker of  
859 Inflammation. *Int. J. Inflamm.* **2012**, 1–6 (2012).
- 860 34. Gorrell, M. D., Gysbers, V. & McCaughan, G. W. CD26: a multifunctional integral membrane  
861 and secreted protein of activated lymphocytes. *Scand. J. Immunol.* **54**, 249–264 (2001).
- 862 35. Abbas, A. K., Lichtman, A. H., Pillai, S., Baker, D. L. & Baker, A. *Cellular and molecular*  
863 *immunology*. (Elsevier, 2018).
- 864 36. Galbraith, M. D. *et al.* Specialized interferon action in COVID-19. *Proc. Natl. Acad. Sci.* **119**,  
865 e2116730119 (2022).
- 866 37. Weigang, S. *et al.* Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-  
867 19 patient as a source of immune escape variants. *Nat. Commun.* **12**, 6405 (2021).
- 868 38. Scherer, E. M. *et al.* SARS-CoV-2 Evolution and Immune Escape in Immunocompromised  
869 Patients. *N. Engl. J. Med.* **386**, 2436–2438 (2022).
- 870 39. Sabbaghi, A. *et al.* Role of  $\gamma\delta$  T cells in controlling viral infections with a focus on influenza  
871 virus: implications for designing novel therapeutic approaches. *Viol. J.* **17**, 174 (2020).
- 872 40. Colonna-Romano, G. *et al.* Gamma/delta T lymphocytes are affected in the elderly. *Exp.*  
873 *Gerontol.* **37**, 205–211 (2002).
- 874 41. Varchetta, S. *et al.* Unique immunological profile in patients with COVID-19. *Cell. Mol.*  
875 *Immunol.* **18**, 604–612 (2021).
- 876 42. Yoo, J.-S. *et al.* SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the  
877 STAT1-IRF1-NLRC5 axis. *Nat. Commun.* **12**, 6602 (2021).
- 878 43. Schnittman, S. R. & Hunt, P. W. Clinical consequences of asymptomatic cytomegalovirus in  
879 treated human immunodeficiency virus infection. *Curr. Opin. HIV AIDS* **16**, 168–176 (2021).



- 880 44. Rasa, S. M. M. *et al.* Inflammaging is driven by upregulation of innate immune receptors and  
881 systemic interferon signaling and is ameliorated by dietary restriction. *Cell Rep.* **39**, 111017  
882 (2022).
- 883 45. Mudd, P. A. *et al.* Distinct inflammatory profiles distinguish COVID-19 from influenza with  
884 limited contributions from cytokine storm. *Sci. Adv.* **6**, eabe3024 (2020).
- 885 46. Bost, P. *et al.* Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.  
886 *Cell* **181**, 1475-1488.e12 (2020).
- 887 47. Jung, C. *et al.* Steroid use in elderly critically ill COVID-19 patients. *Eur. Respir. J.* **58**,  
888 2100979 (2021).
- 889 48. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-  
890 19 — Preliminary Report. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2021436.
- 891 49. Kalantar, K. L. *et al.* IDseq—An open source cloud-based pipeline and analysis service for  
892 metagenomic pathogen detection and monitoring. *GigaScience* **9**, g1aa111 (2020).
- 893 50. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* **29**, (2013).
- 894 51. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-  
895 throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).
- 896 52. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and  
897 microarray studies. *Nucleic Acids Res.* **43**, e47–e47 (2015).
- 898  
899

#### 900 **ACKNOWLEDGMENTS:**

901 **Clinical and Data Coordinating Center:** Sanya Thomas, Mitchell Cooney, Shun Rao, Sofia  
902 Vignolo, Elena Morrocchi. **David Geffen School of Medicine at the University of California-**  
903 **Los Angeles:** Arash Naeim, Marianne Bernardo, Sarahmay Sanchez, Shannon Intluxay, Clara  
904 Magyar, Jenny Brook, Estefania Ramires-Sanchez, Megan Llamas, Claudia Perdomo, Clara E.  
905 Magyar, Jennifer A. Fulcher, and the UCLA Center for Pathology Research Services and the  
906 Pathology Research Portal. **Yale School of Medicine:** M. Catherine Muenker, Dimitri Duvilaire,  
907 Maxine Kuang, William Ruff, Khadir Raddassi, Denise Shepherd, Haowei Wang, Omkar  
908 Chaudhary, Syim Salahuddin, John Fournier, Michael Rainone, Maxine Kuang.

909

#### 910 **Funding:**

911 The study was funded by the United States National Institutes of Health through the following  
912 grants: 5R01AI135803-03, 5U19AI118608-04, 5U19 AI128910-04, 5U19 AI089992,  
913 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17,  
914 5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-

915 03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, NIH-NIAID 3U19AI1289130 and  
916 U19AI128913-04S1 for EFR, R01 AI122220 for CC.

917

918 **Author contributions:**

919 C.R.L. conceived the idea for the project. H.V.P., A.T., C.P.M. and B.L. analyzed the data. E.K.H.,  
920 P.M.B., S.K.S., J.C., A.H., H.P., P.v.Z., M.C.A., A.D.A., C.S.C., S.B., C.C., W.E., L.G., N.D.J.,  
921 S.H.K., F.K., H.T.M., A.O., B.P., N.R., R.R.M., E.R., J.S., H.S., O.L. and J.D.A. provided guidance.  
922 H.V.P., A.T. and C.R.L. wrote the manuscript. All authors reviewed and edited the manuscript.

923

924 **Data and code availability**

925 Data files are available at ImmPort under accession number SDY1760 and dbGAP accession  
926 number phs002686.v1.p1. All analysis code has been deposited at  
927 [https://bitbucket.org/kleinstein/impacc-public-code/src/master/aging\\_manuscript/](https://bitbucket.org/kleinstein/impacc-public-code/src/master/aging_manuscript/).


928

## Supplementary Materials


**Supplementary Table 1. Clinical and demographic characteristics of the cohort at baseline (Visit 1).** P values were calculated using Chi-square test for categorical variables, and Kruskal-Wallis test for continuous variables. Percentages might not sum to 100% due to rounding. The number of patients who died within 28 days is the same as the number of patients in trajectory group 5 (TG5).

Demographics		Overall population n = 1031	Age group [18,46] n = 206	Age group [47,54] n = 187	Age group [55,62] n = 216	Age group [63,70] n = 199	Age group [71,96] n = 223	P-value
Age at enrollment (years), median (IQR) (n=1031)		59.0 (20.0)	37.0 (11.0)	51.0 (4.0)	59.0 (4.0)	67.0 (5.0)	77.0 (8.0)	<0.001
Sex, No. (%)	Male	639 (62%)	128 (62%)	108 (58%)	135 (63%)	123 (62%)	145 (65%)	0.68
	Female	392 (38%)	78 (38%)	79 (42%)	81 (38%)	76 (38%)	78 (35%)	
Race, No. (%)	White	517 (50%)	79 (38%)	85 (45%)	95 (44%)	118 (59%)	140 (63%)	0.002
	Black/ African American	228 (22%)	49 (24%)	47 (25%)	53 (25%)	35 (18%)	44 (20%)	
	Asian	40 (4%)	12 (6%)	6 (3%)	6 (3%)	9 (5%)	7 (3%)	
	Other/Declined/ Unknown	246 (24%)	66 (32%)	49 (26%)	62 (29%)	37 (19%)	32 (14.3%)	
Ethnicity, No. (%)	Non-Hispanic	670 (65%)	114 (55%)	120 (64%)	119 (55%)	137 (69%)	180 (81%)	<0.001
	Hispanic	319 (31%)	82 (40%)	63 (34%)	83 (38%)	57 (29%)	34 (15%)	
	Unknown	42 (4%)	10 (5%)	4 (2%)	14 (6%)	5 (3%)	9 (4%)	
Comorbidities, No. (%)	None	65 (6%)	23 (11%)	13 (7%)	11 (5%)	10 (5%)	8 (4%)	
	Hypertension	592 (57%)	57 (28%)	96 (51%)	134 (62%)	141 (71%)	164 (74%)	<0.001
	Diabetes	384 (37%)	45 (22%)	67 (36%)	90 (42%)	95 (48%)	87 (39%)	<0.001
	Chronic lung disease	208 (20%)	14 (7%)	22 (12%)	43 (20%)	54 (27%)	75 (34%)	<0.001
	Asthma	149 (14%)	34 (17%)	30 (16%)	28 (13%)	36 (18%)	21 (9%)	0.085
	Chronic cardiac disease	282 (27%)	18 (9%)	38 (20%)	55 (25%)	70 (35%)	101 (45%)	<0.001
	Chronic kidney disease	155 (15%)	17 (8%)	22 (12%)	41 (19%)	31 (16%)	44 (20%)	0.004
	Chronic liver disease	51 (5%)	4 (2%)	9 (5%)	14 (6%)	14 (7%)	10 (4%)	0.14
	Chronic neurological disorder	123 (12%)	11 (5%)	13 (7%)	22 (10%)	21 (11%)	56 (25%)	<0.001
	Organ Transplantation	47 (5%)	7 (3%)	10 (5%)	16 (7%)	13 (7%)	1 (0%)	0.004
	HIV/AIDS	13 (1%)	3 (1%)	3 (2%)	6 (3%)	1 (1%)	0 (0%)	0.092
	Malignancy	101 (10%)	9 (4%)	6 (3%)	17 (8%)	25 (13%)	44 (20%)	<0.001
BMI Category in Kg/m <sup>2</sup> , No. (%)	Underweight	12 (1%)	3 (1%)	1 (1%)	1 (0%)	4 (2%)	3 (1%)	<0.001
	Normal weight	145 (14%)	19 (9%)	17 (9%)	19 (9%)	27 (14%)	63 (28%)	
	Overweight (25.1- 29.9)	265 (26%)	41 (20%)	43 (23%)	58 (27%)	52 (26%)	71 (32%)	
	Class 1-2 Obesity (30-39.9)	424 (41%)	82 (40%)	84 (45%)	100 (46%)	85 (43%)	73 (33%)	


	Class 3 Obesity (40+)	147 (14%)	44 (21%)	38 (20%)	31 (14%)	23 (12%)	11 (5%)	
	Missing	38 (4%)	17 (8%)	4 (2%)	7 (3%)	8 (4%)	2 (1%)	
Length of hospital stay (days), median (IQR) (n=890)		6.0 (8.0)	5.0 (5.0)	5.5 (6.5)	6.0 (7.0)	7.0 (8.0)	8.0 (11.0)	<0.001
At baseline visit (V1)								
7-point respiratory Ordinal Score (OS), No. (%)	Mechanically ventilated or ECMO (OS=6)	126 (12%)	19 (9%)	27 (14%)	31 (14%)	25 (13%)	24 (11%)	0.002
	Non-invasive ventilation or high flow O2 (OS=5)	235 (23%)	32 (16%)	30 (16%)	52 (24%)	63 (32%)	58 (26%)	
	Supplemental oxygen (not high flow) (OS=4)	443 (43%)	92 (45%)	82 (44%)	91 (42%)	78 (39%)	100 (45%)	
	None (OS=3)	225 (22%)	63 (31%)	47 (25%)	41 (19%)	33 (17%)	41 (18%)	
	Missing	2 (0%)	0 (0%)	1 (1%)	1 (0%)	0 (0%)	0 (0%)	
SpO2/FiO2 ratio category, No. (%)	235 or lower	246 (24%)	29 (14%)	45 (24%)	49 (23%)	64 (32%)	59 (26%)	0.002
	236-315	170 (16%)	32 (16%)	26 (14%)	43 (20%)	36 (18%)	33 (15%)	
	315 or higher	566 (55%)	137 (67%)	108 (58%)	113 (52%)	93 (47%)	115 (52%)	
	Missing	49 (5%)	8 (4%)	8 (4%)	11 (5%)	6 (3%)	16 (7%)	
Lymphopenia, No. (%)	<500/microliter	132 (13%)	13 (6%)	19 (10%)	32 (15%)	28 (14%)	40 (18%)	0.004
Thrombocytopenia, No. (%)	<100,000/microliter	53 (5%)	3 (1%)	8 (4%)	13 (6%)	15 (8%)	14 (6%)	0.054
D-dimer, No. (%)	>0.5 mg/L	542 (53%)	91 (44%)	83 (44%)	126 (58%)	108 (54%)	134 (60%)	<0.001
Creatinine, No. (%)	>=1.5 mg/dL	169 (16%)	18 (9%)	25 (13%)	43 (20%)	31 (16%)	52 (23%)	<0.001
CRP, No. (%)	>=10 mg/L	446 (43%)	71 (34%)	88 (47%)	99 (46%)	95 (48%)	93 (42%)	0.04
Across all visits (V1-V6)								
IMPACC trajectory group, No. (%)	TG1	217 (21%)	60 (29%)	44 (24%)	41 (19%)	38 (19%)	34 (15%)	<0.001
	TG2	270 (26%)	71 (34%)	57 (30%)	53 (25%)	45 (23%)	44 (20%)	
	TG3	251 (24%)	52 (25%)	44 (24%)	56 (26%)	43 (22%)	56 (25%)	
	TG4	191 (19%)	20 (10%)	33 (18%)	44 (20%)	51 (26%)	43 (19%)	
	TG5	102 (10%)	3 (1%)	9 (5%)	22 (10%)	22 (11%)	46 (21%)	
28-day mortality, No. (%)	Yes	102 (10%)	3 (1%)	9 (5%)	22 (10%)	22 (11%)	46 (21%)	<0.001
	No	929 (90%)	203 (99%)	178 (95%)	194 (90%)	177 (89%)	177 (79%)	
Treatment with steroids, No. (%)	Yes	711 (69%)	124 (60%)	137 (73%)	150 (69%)	155 (78%)	145 (65%)	0.001
	No	320 (31%)	82 (40%)	50 (27%)	66 (31%)	44 (22%)	78 (35%)	
Treatment with remdesivir, No. (%)	Yes	645 (63%)	122 (59%)	114 (61%)	133 (62%)	137 (69%)	139 (62%)	0.33
	No	386 (37%)	84 (41%)	73 (39%)	83 (38%)	62 (31%)	84 (38%)	




**Supplementary Figure 1. Comparison of viral load as measured by nasal swab qPCR and nasal swab RNA-seq (metatranscriptomics).** The Pearson's correlation coefficient and its P value are shown below each panel.




**Supplementary Figure 2. Time since symptom onset across age groups at Visit 1.** Data is available for a subset of patients (n=796 of 963 Visit 1 samples). Two outliers with >40 days since symptom onset are excluded from the plot. P value is calculated by one-way ANOVA test.



**Supplementary Figure 3. Visit 1 analysis and longitudinal analysis of IgG levels.** (a) RBD IgG at visit 1 in each age group. P-value determined by likelihood ratio test. (b) RBD IgG levels, as measured by area under the curve (AUC, see methods), over time in each age group. P-value determined by a generalized additive mixed model. Values plotted represent the area under the curve of the optical density (OD).




**Supplementary Figure 4. Visit 1 analysis of CyTOF data while controlling for viral load.** Bar plot highlighting cell types that are significantly associated with age ( $P < 0.05$ , calculated with linear regression and Benjamini-Hochberg correction). Analogous to the analyses in Figure 3b, but controlled for viral load.




**Supplementary Figure 5. Comparison of PBMC RNA-seq data from this study to healthy control datasets<sup>5</sup>, with differential gene expression analyses performed using age as a continuous variable.** (a, b) Venn diagrams of the Reactome pathways that are (a) upregulated and (b) downregulated with age. The numbers in the left circles indicate the number of pathways that are up- or down-regulated with age in the healthy control data only. The numbers in the right circles indicate the number of pathways that are up- or down-regulated with age in COVID-19 patients (our data) only. The numbers in the overlapping regions indicate the number of pathways that are up- or down-regulated with age in both healthy control and COVID-19 patients. Some examples of overlapping pathways, and of pathways that are associated with age in COVID-19 patients only are included under each Venn diagram.






**Supplementary Figure 6. Plots of the dynamics of 6 example genes in PBMC samples.**


Black lines indicate the regression lines for the fixed effects of the linear mixed-effects model. The grey ribbons indicate the 95% confidence intervals of the regression lines. The y-axes were truncated at  $1.5\times$  the interquartile range below the first quartile and above the third quartile. P values are calculated using the likelihood ratio test and Benjamini-Hochberg correction.




**Supplementary Figure 7. Effect of SARS-CoV-2 viral load on age-cytokine relationship at Visit 1, and the dynamics of 4 example cytokines.** (a) Bar plot depicting cytokines associated with age ( $P < 0.05$ , calculated with linear regression and Benjamini-Hochberg correction), while controlling for SARS-CoV-2 viral load. Supplementary Figure 6a differs from Figure 4a in that the former controlled for viral load, while the latter did not. (b) Plots demonstrating the dynamics of four cytokines TNFSF11, CXCL8, CXCL9, and IL6. Black lines indicate the regression lines for the fixed effects of the linear mixed-effects model. The grey ribbons indicate the 95% confidence intervals of the regression lines. The y-axes were truncated at  $1.5 \times$  the interquartile range below the first quartile and above the third quartile. P values were calculated using the likelihood ratio test and Benjamini-Hochberg correction.




**Supplementary Figure 8. Bacterial load (reads per million, rpM) versus age quintiles.** Total bacterial abundance (log-transformed rpM, as measured by nasal metatranscriptomics) in each of the age quintiles. P value was calculated with one-way ANOVA test.



**Supplementary Figure 9. Aging and COVID-19 severity, analyses controlled for viral load.** (a, b) Dot plots depicting a) select Reactome pathways in PBMC or nasal RNA-seq data, and b) serum cytokines (olink) that were upregulated in severe patients (NIAID ordinal scales 5-6) compared to mild/moderate (NIAID ordinal scales 3-4) patients at Visit 1, stratified by age group (youngest or oldest). Analogous analyses to Fig. 7, but controlled for viral load.



**Supplementary Figure 10. Expression of interferon-related genes in patients with or without anti-IFN $\alpha$  antibodies at Visit 1.** Normalized gene expression is plotted for the subset of samples with both PMBC RNA-seq and anti-IFN $\alpha$  antibody data available (n=732 visit 1 samples). All genes from the Reactome interferon alpha/beta signaling pathway with an adjusted P-value < 0.05 are included (n=18).



**Supplementary Figure 11. Network analysis of the top 10 significant serum proteins and their receptors and downstream signaling.** PBMC RNA-seq and serum cytokine data was integrated using Cytoscape.

**Supplementary Table 2.** Prevalence of viral cases by age quintile over time in the nasal virome. Adjusted P values (P adj, Benjamini-Hochberg method) are determined by ANOVA with respect to change in prevalence of virus over time within each age quintile. HHV = human herpes virus, CMV = cytomegalovirus, EBV = Epstein Barr virus, HSV = herpes simplex virus.

Virus	Age Quintile	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	P adj
CMV (HHV-5)	[18,46]	0.52% (1/191)	1.01% (1/99)	0% (0/53)	1.61% (1/62)	0% (0/4)	0% (0/39)	1.0
	[47,54]	0% (0/175)	0.95% (1/105)	1.61% (1/62)	1.79% (1/56)	0% (0/17)	0% (0/36)	0.61
	[55,62]	0.49% (1/205)	0% (0/128)	0% (0/79)	0% (0/70)	0% (0/20)	0% (0/42)	1.0
	[63,70]	0% (0/190)	1.79% (2/112)	1.24% (1/81)	1.49% (1/67)	4.17% (1/24)	3.03% (1/33)	0.24
	[71,96]	0.47% (1/212)	0% (0/133)	0% (0/94)	1.27% (1/79)	11.54% (3/26)	6.90% (2/29)	1.70E-03
	[18,46]	0% (0/191)	0% (0/99)	0% (0/53)	0% (0/62)	0% (0/4)	0% (0/39)	1.0
EBV (HHV-4)	[47,54]	1.14% (2/175)	3.8% (4/105)	1.61% (1/62)	0% (0/56)	0% (0/17)	0% (0/36)	0.71
	[55,62]	0.49% (1/205)	2.34% (3/128)	2.53% (2/79)	4.29% (3/70)	5.0% (1/20)	4.76% (2/42)	0.24
	[63,70]	1.58% (3/190)	0.89% (1/112)	4.94% (4/81)	2.99% (2/67)	8.33% (2/24)	0% (0/33)	0.24
	[71,96]	0% (0/212)	1.50% (2/133)	4.26% (4/94)	1.27% (1/79)	7.70% (2/26)	3.45% (1/29)	0.039
	[18,46]	0% (0/191)	0% (0/99)	0% (0/53)	1.61% (1/62)	0% (0/4)	2.56% (1/39)	0.24
Pegivirus	[47,54]	0.57% (1/175)	1.9% (2/105)	1.6% (1/62)	5.36% (3/56)	0% (0/17)	5.56% (2/36)	0.24
	[55,62]	0.98% (2/205)	0.78% (1/128)	0% (0/79)	1.43% (1/70)	0% (0/20)	0% (0/42)	1.0
	[63,70]	0% (0/190)	0% (0/112)	0% (0/81)	0% (0/67)	0% (0/24)	0% (0/33)	1.0
	[71,96]	0% (0/212)	0% (0/133)	0% (0/94)	1.27% (1/79)	0% (0/26)	0% (0/29)	0.43
	[18,46]	4.71% (9/191)	8.08% (8/99)	9.43% (5/53)	3.23% (2/62)	0% (0/4)	2.56% (1/39)	0.71
HSV (HHV-1/2)	[47,54]	3.43% (6/175)	5.71% (6/105)	6.45% (4/62)	7.14% (4/56)	11.77% (2/17)	5.56% (2/36)	0.71
	[55,62]	2.44% (5/205)	6.25% (8/128)	8.86% (7/79)	11.43% (8/70)	5.0% (1/20)	9.52% (4/42)	0.13
	[63,70]	3.16% (6/190)	5.36% (6/112)	12.35% (10/81)	13.43% (9/67)	12.50% (3/24)	6.06% (2/33)	0.056
	[71,96]	2.36% (5/212)	5.26% (7/133)	4.26% (4/94)	16.46% (13/79)	30.77% (8/26)	17.24% (5/29)	4.50E-06